ATNMActinium PharmaceuticalsRunning, no new patients
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia · Leukemia, Acute Myeloid · Myeloid Leukemia, Acute · Leukemia, Myeloid, Acute · Acute Myelogenous Leukemia · Leukemia, Acute Myelogenous · Myelogenous Leukemia, Acute · AML · Bone Marrow Transplant
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2022, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 153 (final count)
- Started
- Jun 2016
- Main results expected
- Jun 2022
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Durable Complete Remission (dCR)
Measured over: 6 months from time of initial CR or CRp
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2022-06-01, no fading
Raw record changes
- none yet
Trial ID NCT02665065 · record last updated 2023-07-19 · checked 2026-11-09 15:47 UTC